Choroidal Melanoma Bibliography

COMS

Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings, COMS report no. 18. Arch Ophthalmol. 2001;119(7):969-982. doi:10.1001/archopht.119.7.969.

Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings, COMS report no. 18. Arch Ophthalmol. 2001;119(7):969-982. doi:10.1001/archopht.119.7.969.

Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, V: twelve-year mortality rates and prognostic factors, COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684-1693. doi:10.1001/archopht.124.12.1684.

Diener-West M, Reynolds SM, Agugliaro DJ, et al; Collaborative Ocular Melanoma Study Group Report 23. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group report 23. J Clin Oncol. 2004;22(12):2438-2444. doi:10.1200/JCO.2004.08.194.

Hawkins BS; Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors, COMS report number 24. Am J Ophthalmol. 2004;138(6):936-951. doi:10.1016/j.ajo.2004.07.006.

Margo CE. The Collaborative Ocular Melanoma Study: an overview. Cancer Control. 2004;11(5):304-309. doi:10.1177/107327480401100504.

The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma: COMS report no. 5. Arch Ophthalmol. 1997;115(12):1537-1544. 


Melanoma Diagnosis and Management

Bechrakis NE, Petousis V, Willerding G, et al. Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate [published online December 3, 2009]. Br J Ophthalmol. 2010;94(4):460-466. doi:10.1136/bjo.2009.162487.

Finger PT, Chin KJ, Yu GP; Palladium-103 for Choroidal Melanoma Study Group. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma [published online February 6, 2010]. Am J Ophthalmol. 2010;149(4):608-615. doi:10.1016/j.ajo.2009.11.006.

Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118(6):773-778. doi:10.1001/archopht.118.6.773.

Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology. 1999;106(8):1571-1577. doi:10.1016/S0161-6420(99)90455-4.

Harbour JW, Meredith TA, Thompson PA, Gordon ME. Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. Ophthalmology. 2003;110(11):2207-2214 doi:10.1016/S0161-6420(03)00858-3.

Hawkins BS; Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, IV: ten-year mortality findings and prognostic factors, COMS report number 24. Am J Ophthalmol. 2004;138(6):936-951. doi:10.1016/j.ajo.2004.07.006.

Murray TG, Gold AS, Markoe AM, et al. Spectral-domain optical coherence tomography evaluation of choroidal melanoma and nevus fine-needle aspiration biopsy incision sites. Ophthalmic Surg Lasers Imaging Retina. 2014;45(2):165-168. doi:10.3928/23258160-20140306-11.

Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23(31):8076-8080. doi:10.1200/JCO.2005.02.6534.

Schmittel A, Bechrakis NE, Martus P, et al. Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma. Eur J Cancer. 2004;40(16):2389-2395. doi:10.1016/j.ejca.2004.06.028.

Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol. 2009;127(8):981-987. doi:10.1001/archophthalmol.2009.151.

Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219-1228. doi:10.1001/archopht.118.9.1219.

Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology. 2002;109(2):225-234. doi:10.1016/S0161-6420(01)00902-2.

Straatsma BR, Diener-West M, Caldwell R, Engstrom RE; Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol. 2003;136(1):47-54. doi:10.1016/S0002-9394(02)02270-5.


Melanoma Genetics

Aaberg TM Jr, Cook RW, Oelschlager K, et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol. 2014;8:2449-2460. doi:10.2147/OPTH.S70839.

Field MG, Durante MA, Decatur CL, et al. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in class 1 and class 2 uveal melanomas. Oncotarget. 2016;7(37):59209-59219. doi:10.18632/oncotarget.10962.

Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234-239. doi:10.1097/ICU.0000000000000051.

Field MG1, Decatur CL1, Kurtenbach S, et al. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res. 2016;22(5):1234-1242. doi:10.1158/1078-0432.CCR-15-2071.

Griewank KG, van de Nes J, Schilling B, et al. Genetic and clinico-pathologic analysis of metastatic uveal melanoma [published online July 26, 2013]. Mod Pathol. 2014;27(2):175-183. doi:10.1038/modpathol.2013.138.

Harbour JW, Chao DL. A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology. 2014;121(6):1281-1288. doi:10.1016/j.ophtha.2013.12.014.

Maerker DA, Zeschnigk M, Nelles J, et al. BAP1 germline mutation in two first grade family members with uveal melanoma. Br J Ophthalmol. 2014;98(2):224-227. doi:10.1136/bjophthalmol-2013-303814.

Midena E, Bonaldi L, Parrozzani R, Radin PP, Boccassini B, Vujosevic S. In vivo monosomy 3 detection of posterior uveal melanoma: 3-year follow-up [published online October 13, 2007]. Graefes Arch Clin Exp Ophthalmol. 2008;246(4):609-614. doi:10.1007/s00417-007-0692-4.

Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families [published online April 24, 2012]. PLoS One. 2012;7(4):e35295. doi:10.1371/journal.pone.0035295.

Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma [published online April 21, 2012]. Ophthalmology. 2012;119(8):1596-1603. doi:10.1016/j.ophtha.2012.02.017.

Onken MD, Worley LA, Char DH, et al. Collaborative Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma [published online April 21, 2012]. Ophthalmology. 2012;119(8):1596-1603. doi:10.1016/j.ophtha.2012.02.017.  

Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma [published online August 21, 2008]. Invest Ophthalmol Vis Sci. 2008;49(12):5230-5234. doi:10.1167/iovs.08-2145.

Onken MD1, Worley LA, Ehlers JP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205-7209. doi:10.1158/0008-5472.CAN-04-1750.

Sandinha MT, Farquharson MA, McKay IC, Roberts F. Monosomy 3 predicts death but not time until death in choroidal melanoma. Invest Ophthalmol Vis Sci. 2005;46(10):3497-3501. doi:10.1167/iovs.05-0613.

Schopper VJ, Correa ZM. Clinical application of genetic testing for posterior uveal melanoma. Int J Retina Vitreous. 2016;2:4. doi:10.1186/s40942-016-0030-2.

Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997;19(1):22-28. doi:10.1002/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2.

UM DecisionDx. DecisionDx-UM Newsletter. March 2017.


Melanoma Mimickers

Fung AT, Fulco EM, Shields CL, et al. Choroidal hemorrhage simulating choroidal melanoma. Retina. 2013;33(8):1726-1728. doi:10.1097/IAE.0b013e31828dac9d.


Review

Shields CL, Kaliki S, Furuta M, et al. American Joint Committee on Cancer Classification of Uveal Melanoma (anatomic stage) predicts prognosis in 7,731 patients: The 2013 Zimmerman Lecture [published online March 24, 2015]. Ophthalmology. 2015;122(6):1180-1186. doi:10.1016/j.ophtha.2015.01.026.

Shields JA, Shields CL. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture [published online October 14, 2014]. Ophthalmology. 2015;122(2):414-428. doi:10.1016/j.ophtha.2014.08.046.


TTT

Mashayekhi A, Shields CL, Rishi P, et al. Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control [published online November 14,014]. Ophthalmology. 2015;122(3):600-609. doi:10.1016/j.ophtha.2014.09.029. 


Updated February 2018

Designed and built in Chicago by Webitects